Related references
Note: Only part of the references are listed.Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
S. S. Ramalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
TATTON: a multi-arm, phase lb trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
G. R. Oxnard et al.
ANNALS OF ONCOLOGY (2020)
Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response
Ben Sidders et al.
CLINICAL CANCER RESEARCH (2020)
Ectonucleotidase CD39 and Checkpoint Signalling Receptor Programmed Death 1 are Highly Elevated in Intratumoral Immune Cells in Non-small-cell Lung Cancer
Anders Tondell et al.
TRANSLATIONAL ONCOLOGY (2020)
The Roles of CD38 and CD157 in the Solid Tumor Microenvironment and Cancer Immunotherapy
Yu Jun Wo et al.
CELLS (2020)
Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP)
Alejandro Ruiz-Patino et al.
THORACIC CANCER (2020)
Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC
Hidenobu Ishii et al.
THORACIC CANCER (2020)
Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations
Martin Reck et al.
EXPERT REVIEW OF RESPIRATORY MEDICINE (2020)
Targeting the CD73-adenosine axis in immuno-oncology
David Allard et al.
IMMUNOLOGY LETTERS (2019)
EGFR-targeted therapy alters the tumor microenvironment in EGFR-driven lung tumors: Implications for combination therapies
Yijun Jia et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report
James Chih-Hsin Yang et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation
James Chih-Hsin Yang et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing
Jingsi Dong et al.
FRONTIERS IN PHARMACOLOGY (2019)
The metabolic milieu in melanoma: Role of immune suppression by CD73/adenosine
Anna Passarelli et al.
TUMOR BIOLOGY (2019)
Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies
Ivan Perrot et al.
CELL REPORTS (2019)
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
K. Hastings et al.
ANNALS OF ONCOLOGY (2019)
Tumor-derived exosomes promote the in vitro osteotropism of melanoma cells by activating the SDF-1/CXCR4/CXCR7 axis
Francesco Mannavola et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Antoni Ribas et al.
NATURE MEDICINE (2019)
Lack of clearly defined role for anti-programmed death-(ligand) 1 therapy in epidermal growth factor receptor mutated non-small cell lung cancer
Aaron Lisberg et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2019)
Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations
Anqi Lin et al.
MOLECULAR CANCER (2019)
Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities
Antonio Santaniello et al.
CANCERS (2019)
Efficacy of Immune-Checkpoint Inhibitors and EGFR-TKIs in NSCLC Patients with High PD-L1 Expression
K. Masuda et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells
Marco Tucci et al.
FRONTIERS IN ONCOLOGY (2019)
Immunotherapy for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
Pablo Martinez et al.
CLINICAL CANCER RESEARCH (2019)
Adenosine Metabolism: Emerging Concepts for Cancer Therapy
Detlev Boison et al.
CANCER CELL (2019)
First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?
Masayuki Takeda et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Diagnosis and first-line treatment of non-small cell lung cancer in the era of novel immunotherapy: recommendations for clinical practice
Filippo De Marinis et al.
EXPERT REVIEW OF RESPIRATORY MEDICINE (2019)
CD39 increase on cytotoxic T-cell induced by myeloid-derived suppressor cell correlated with poor prognosis in patients with non-small cell lung cancer
Jiae Koh et al.
CANCER IMMUNOLOGY RESEARCH (2019)
The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma
Tucci Marco et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Immune checkpoint inhibitor treatment in patients with oncogene-addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary roundtable discussion
Anna S. Berghoff et al.
ESMO OPEN (2019)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
Hira Rizvi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naive Patients With Advanced NSCLC
A. Lisberg et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
PD-L1 expression according to the EGFR status in primary lung adenocarcinoma
Kazuki Takada et al.
LUNG CANCER (2018)
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
M. A. Socinski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade
Limo Chen et al.
CANCER DISCOVERY (2018)
CD73 expression and clinical significance in human metastatic melanoma
Inês Monteiro et al.
Oncotarget (2018)
Cytokine-Induced Killer Cells Express CD39, CD38, CD203a, CD73 Ectoenzymes and P1 Adenosinergic Receptors
Alberto L. Horenstein et al.
FRONTIERS IN PHARMACOLOGY (2018)
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma A Systematic Review and Meta-analysis
Chee Khoon Lee et al.
JAMA ONCOLOGY (2018)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D. Planchard et al.
ANNALS OF ONCOLOGY (2018)
Immunometabolism in cancer at a glance
Katrin Singer et al.
DISEASE MODELS & MECHANISMS (2018)
Immunologic and clinical implications of CD73 expression in non-small cell lung cancer (NSCLC).
Lee Chun Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations
Maria I. Toki et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Overcoming Acquired PD-1/PD-L1 Resistance with CD38 Blockade
Deepak Mittal et al.
CANCER DISCOVERY (2018)
A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti-PD-(L)1 and Anti-CTLA-4 in Preclinical Models
Stephen B. Willingham et al.
CANCER IMMUNOLOGY RESEARCH (2018)
The biology and management of non-small cell lung cancer
Roy S. Herbst et al.
NATURE (2018)
The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets
Bertrand Allard et al.
IMMUNOLOGICAL REVIEWS (2017)
Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer A Meta-Analysis
Chee Khoon Lee et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management (Review)
Stefania Stucci et al.
ONCOLOGY LETTERS (2017)
Immune system and melanoma biology: a balance between immunosurveillance and immune escape
Anna Passarelli et al.
ONCOTARGET (2017)
Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer
Yusuke Inoue et al.
ONCOTARGET (2017)
Editorial: Immuno-Metabolism in Tumor Microenvironment
Heriberto Prado-García et al.
Frontiers in Immunology (2017)
CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF--mTOR-HIF-1 signaling in patients with non-small cell lung cancer
Jieyao Li et al.
ONCOIMMUNOLOGY (2017)
EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer
Zhong-Yi Dong et al.
ONCOIMMUNOLOGY (2017)
Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients.
Lawrence Fong et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Increased CD73 and reduced IFNG signature expression in relation to response rates to anti-PD-1(L1) therapies in EGFR-mutant NSCLC.
Katie Streicher et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naive patients (pts) with EGFR mutant NSCLC
D. L. Gibbons et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Emerging concepts of T cell metabolism as a target of immunotherapy
Chih-Hao Chang et al.
NATURE IMMUNOLOGY (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
A Metabolic immune Checkpoint: Adenosine in Tumor Microenvironment
Akio Ohta
FRONTIERS IN IMMUNOLOGY (2016)
Targeting CD73 in the tumor microenvironment with MEDI9447
Carl M. Hay et al.
ONCOIMMUNOLOGY (2016)
Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer
Jin S. Im et al.
PLOS ONE (2016)
Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies.
David R. Spigel et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Classifying Cancers Based on T-cell Infiltration and PD-L1
Michele W. L. Teng et al.
CANCER RESEARCH (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses
Paul A. Beavis et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth
Melanie Mediavilla-Varela et al.
CANCER BIOLOGY & THERAPY (2013)
Epidermal Growth Factor Receptor-Containing Exosomes Induce Tumor-Specific Regulatory T Cells
Shao-hong Huang et al.
CANCER INVESTIGATION (2013)
Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs
Bertrand Allard et al.
CLINICAL CANCER RESEARCH (2013)
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.
Esra A. Akbay et al.
MOLECULAR CANCER THERAPEUTICS (2013)
A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes
Alberto L. Horenstein et al.
ONCOIMMUNOLOGY (2013)
Adenosine Deaminase in the Modulation of Immune System and its Potential as a Novel Target for Treatment of Inflammatory Disorders
Luca Antonioli et al.
CURRENT DRUG TARGETS (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis
John Stagg et al.
CANCER RESEARCH (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Epidermal Growth Factor Receptor Inhibition Augments the Expression of MHC Class I and II Genes
Brian P. Pollack et al.
CLINICAL CANCER RESEARCH (2011)
International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors-An Update
Bertil B. Fredholm et al.
PHARMACOLOGICAL REVIEWS (2011)
Extracellular adenosine triphosphate and adenosine in cancer
J. Stagg et al.
ONCOGENE (2010)
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis
John Stagg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Share Paper
